Five Reasons That Many Comparative Effectiveness Studies Fail To Change Patient Care And Clinical Practice | Justin W. Timbie | 2168-2175 | 2012.10.26 | - | |
(The) Patient-Centered Outcomes Research Institute Should Focus On High-Impact Problems That Can Be Solved Quickly | Harold Sox | 2176-2182 | 2012.10.26 | - | |
Communicating About Comparative Effectiveness Research | Susan Dentzer | 2183-2187 | 2012.10.26 | - | |
Regulatory Requirements Of The Food And Drug Administration Would Preclude Product Claims Based On Observational Research | Joseph P. Griffin | 2188-2192 | 2012.10.26 | - | |
Reviewing Hypothetical Migraine Studies Using Funding Criteria From The Patient-Centered Outcomes Research Institute | Joe V. Selby | 2193-2199 | 2012.10.26 | - | |
(The) Food And Drug Administration Has The Legal Basis To Restrict Promotion Of Flawed Comparative Effectiveness Research | Aaron S. Kesselheim | 2200-2205 | 2012.10.26 | - | |
Academic Detailing Can Play A Key Role In Assessing And Implementing Comparative Effectiveness Research Findings | Michael A. Fischer | 2206-2212 | 2012.10.26 | - | |
Communication About Results Of Comparative Effectiveness Studies | Eleanor M. Perfetto | 2213-2219 | 2012.10.26 | - | |
Congress Should Clarify The Circumstances Under Which Drug Makers Can Communicate Results On Comparative Effectiveness | Coleen Klasmeier | 2220-2224 | 2012.10.26 | - | |
The Hypothetical Migraine Drug Comparative Effectiveness Study | Robert S. Epstein | 2225-2230 | 2012.10.26 | - | |